News

Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials

May 30, 2024/

A pioneering once-a-day pill that regenerates nerve cell connections damaged by ALS has been FDA-approved for ongoing clinical trials. The drug is now being given to those with ALS and could be a watershed moment in the treatment of the fatal disease.

By Paul McClure


Click here to read the story.

Related Stories

No related posts.

Leave a Comment

You must be logged in to post a comment.

MATR Sponsor (view all)


"For small to medium to national organizations, for events and fundraisers of any size, in any format – live, virtual or hybrid – the platform is built for scale."

MATR Supporters (view all)


ADROIT Employer Resources is a Montana-based workforce and talent solutions partner

The Great Falls Development Alliance delivers aggressive, award-winning economic development support for business attraction, expansion, and retention.

Working closely with GFDA’s economic development team, HPF helps Montana businesses access the capital they need to expand, modernize, and strengthen local communities.